The Meth Sentencing Law Is Still Fighting a Drug That Doesn’t Exist Anymore

Jeffrey Steen had already smoked meth before he sat down across from Jake at a dimly lit restaurant in New York. That was part of what the drug did for him — it took the jagged edge off meeting a stranger from Grindr. Jake, an investment banker with his own years of sobriety, ordered water instead of wine and told Steen something that stuck: “You’re too well put together to be an addict.” Steen didn’t correct him. He was a doctoral student at NYU then, using meth for social anxiety and childhood trauma he’d never had language for, and the drug had already carried him from smoking to injecting without him quite tracking when. Two years later he rented a hotel room on Manhattan’s Upper East Side, sat on the window ledge for hours, and walked out to run — by accident, on York Avenue — into Jake, who got him to a hospital that night. Steen told the story in Filter Magazine in 2021, and almost none of what saved him shows up anywhere in federal drug policy.

Steen got better through harm reduction — using safer, not necessarily using never: avoiding needle-sharing, testing his supply for fentanyl, sitting in therapy groups built for people who still use — combined with a 12-step program. What he didn’t get was a pill. There still isn’t one, not for him then and not for anyone in 2026.

The law still measures methamphetamine using a purity distinction that disappeared from the street years ago, and it is still sending people away for eight years over the difference.

That’s not rhetorical. In February, the U.S. Sentencing Commission — the body that writes the guidelines federal judges use to calculate prison time — opened a formal comment period on rewriting meth sentencing rules untouched since 1988. The window closed February 10. What comes out of it decides how long people go to prison for a drug whose chemistry has completely changed since the rule was written.

A Purity Line the Drug Left Behind

A mandatory minimum, in plain terms, is a sentencing floor Congress writes into law that takes discretion from the judge: once you’re convicted of trafficking a certain quantity, the judge can’t go below a set number of years no matter the circumstances. For meth, that floor has depended since 1988 on a purity threshold — prosecutors calculate your sentence by how chemically pure the batch was, not just how much of it there was. The 1988 guidelines split meth into three tiers — “mixture” (diluted, cut with fillers), “actual” (pure meth by weight), and “ice” (crystallized, 80%-plus pure) — with “actual” and “ice” drawing far harsher sentences than the same weight of “mixture,” because purity was then a reasonable proxy for how close you sat to the top of the supply chain.

It stopped being reasonable years ago. Street meth today runs upward of 90% pure as a baseline, not an exception — the “mixture” tier barely exists anymore. Part of why: the Combat Methamphetamine Epidemic Act, signed in March 2006, moved pseudoephedrine behind pharmacy counters and capped purchases, killing off small-time domestic “shake and bake” labs — and shifting production to industrial cartel operations manufacturing meth at a purity no bathroom chemist ever touched. The law meant to shrink the supply instead professionalized it. The guidelines still assume the amateur version of the drug exists.

The Commission is weighing fixes, per Filter’s reporting: one uniform quantity threshold, or two tiers with case-by-case factors — weapons, coercion, pill-press equipment, dark web sales — that let judges weigh what actually makes a case worse. Either beats sentencing people on a chemistry distinction the market erased. It belongs in Rize’s ongoing coverage of treatment and recovery policy for that reason: a law meant to punish differently by purity now punishes almost everyone at the top of the scale, because purity stopped varying.

This Is Meth’s 1986 Moment, Forty Years Late

The reason meth sentencing looks the way it does traces to a death that had nothing to do with meth. Maryland basketball star Len Bias died of a cocaine overdose on June 19, 1986, two days after the Celtics drafted him. The resulting panic produced the Anti-Drug Abuse Act of 1986, setting a 100-to-1 disparity between crack and powder cocaine: 5 kilograms of powder or just 50 grams of crack triggered the same mandatory 10-year sentence, despite the two being chemically identical. Federal sentences for Black defendants ran 11% longer than white defendants’ in 1986; four years later, 49% longer. In 1998, Congress took that framework and halved meth’s thresholds to match it — the direct line from Bias’s death to today’s rewrite. The ratio wasn’t fixed until the Fair Sentencing Act of 2010 cut it to 18-to-1, a 24-year gap. Meth’s reckoning is arriving four decades late.

In 1998, Congress took that framework and halved meth’s thresholds to match it — the direct line from Bias’s death to today’s rewrite.

One in Four, Eight Years, One Percent

If you’re reading this from inside a federal facility, or you’re the person outside keeping track of someone’s release date, this arithmetic isn’t abstract — it’s the difference between one Thanksgiving and three. Roughly one in four people in the federal Bureau of Prisons is serving time for meth trafficking. The average sentence is eight years, a year and a half longer than the average fentanyl sentence, despite fentanyl killing far more people. Meth shows up in only about 1% of federal overdose cases. The system isn’t calibrated to the harm the drug does; it’s calibrated to a 1998 compromise stacked on a 1988 chemistry test the market no longer respects.

That math isn’t happening in a vacuum. DEA’s Chicago Field Division reported seizing 3,038 pounds of meth between January and July of 2026 alone — already more than all of 2025’s 2,314 pounds — much of it in counterfeit pills sold as fake Adderall or MDMA. Use has climbed fastest in rural counties, where the drug’s profile fits work that doesn’t stop for how a person feels, and treatment infrastructure is thinnest. The psychostimulant death rate more than doubled between 2018 and 2023. More meth is moving; the response on the books is still a purity test from the Reagan era.

No Pill, But Not Nothing

This is where the story becomes about you, if you’re trying to stop using meth right now: there has never been an FDA-approved medication for methamphetamine use disorder — the clinical term for meth use compulsive and disruptive enough to meet a diagnosis — and there still isn’t one in 2026. Not for lack of trying. A JAMA Psychiatry meta-analysis of 12 NIDA-sponsored trials, published in June, pooled nine drugs — topiramate, bupropion, modafinil, ondansetron, tiagabine, cabergoline, reserpine, selegiline, baclofen — and found 31.2% achieved some reduction in use, but only 13.3% reached full abstinence. None cleared FDA approval.

But something real happened this spring. The “Tina Trial,” published in JAMA Psychiatry on April 1, followed 339 adults with moderate-to-severe meth use disorder across six Australian outpatient clinics, testing a common generic antidepressant, mirtazapine, against placebo over 12 weeks. The mirtazapine group cut use by 7 of 28 days; placebo by 4.8. “This is a game-changer,” said lead investigator Dr. Rebecca McKetin of UNSW Sydney’s National Drug and Alcohol Research Centre — “the first clinical trial in the world to definitively confirm that once-daily mirtazapine can be used to treat meth dependence.” Co-investigator A/Prof Shalini Arunogiri added the more honest framing: “Even small reductions in methamphetamine use can translate into meaningful improvements in health and well-being.” Seven fewer days a month isn’t a cure. It’s the first drug to ever definitively beat placebo at this scale, for a disorder that has had nothing.

The FDA has since published draft guidance walking sponsors through how to design trials for stimulant use disorder medications — a framework, not a drug, but an acknowledgment the pipeline needs rules before it can produce anything approvable. Meanwhile the best-evidenced tool clinicians have is contingency management — paying people, usually in small gift cards, for drug tests that come back clean, because that direct incentive has outperformed nearly everything else tried against stimulants. Rize covered that approach and why it remains the field’s strongest option absent a pill. It’s real, and it’s not enough — both true of meth treatment broadly right now.

Steen made it to recovery without any of this — no approved medication, no contingency management, just harm reduction, a 12-step room, and a lucky encounter with a man he’d met on an app. The country’s response to meth has spent 38 years perfecting how to punish the chemistry and almost no time approving anything to treat the person. A quarter of the federal prison system is serving eight years for a purity line the drug itself erased. The best medicine anyone has proven works, so far, buys back seven days a month. Both numbers are the true state of this field in August 2026, and neither is where it should have landed by now.

The best medicine anyone has proven works, so far, buys back seven days a month.